| Ytd | -63.22% | |
| 1y | -85.97% |
| Open | 1.46 | Prev Close | 1.44 | Low | 1.40 | High | 1.67 | Mkt Cap | 11.02M |
| Vol | 211.91K | Avg Vol | 178.81K | EPS | -5.10 | P/E | N/A | Forward P/E | -5.83 |
| Beta | 1.20 | Short Ratio | 13.56 | Inst. Own | 15.83% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 0.94 | 200-d Avg | 3.38 | 1yr Est | 12.75 |
FBLG News
FibroBiologics (NASDAQ:FBLG), a clinical-stage biotechnology company, has released and shipped the t
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-s
HOUSTON, Aug. 27, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-
HOUSTON, Aug. 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the
Legendary Sports Agent, Attorney, and Longtime Advocate for Human Longevity and Brain Health Joins B
Patent covers the use of cannabidiol in combination with fibroblast-based cell therapy to treat dege
FibroBiologics Inc. (NASDAQ:FBLG), a clinical-stage biotechnology company, on Tuesday revealed a sig
FibroBiologics reports promising preclinical results for a novel joint repair therapy, offering a fa
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology compa
Animal trials show cartilage repair within four weeks following a single injection of chondrocyte sp
Patent has potential for applications beyond diabetes, including other cell and tissue transplantati
Patent has potential for applications beyond diabetes, including other cell and tissue transplantati
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-
Granted claims cover Sox9-based conversion of fibroblasts into cartilage-producing cells, supporting
Top Wall Street analysts changed outlook on top names. Complete view of analyst rating changes, incl
HC Wainwright & Co. analyst Matthew Caufield maintains FibroBiologics (NASDAQ:FBLG) with a Bu
FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) reported quarterly losses of $(0.66) per share whi
- First patients dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers - On t
Microbiologist, Retired NASA Astronaut, and Founding Director of the University of Pittsburgh Trived
Company expects existing supply will suffice to complete clinical trial and lead to cost savingsHOUS
Company expects existing supply will suffice to complete clinical trial and lead to cost savings HOU
HOUSTON, June 30, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a cli
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds up
FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics" or the "Company"), a clinical-
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds up
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology compa
Allowed claims directly support the Company's ongoing Phase 1/2 clinical trial of CYWC628 in patient
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology compa
HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a
HOUSTON, June 03, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a
FibroBiologics Inc. (NASDAQ: FBLG) reports enrolling first patients in its Phase 1/2 trial for CYWC6
FibroBiologics Inc. (NASDAQ: FBLG) reports enrolling first patients in its Phase 1/2 trial for CYWC6
Psoriasis is a chronic inflammatory skin disease driven by dysregulated innate and adaptive immunity
In animal studies, human dermal fibroblast spheroids reduce disease severity, prevent relapse, and s
The application covers oral delivery systems designed to protect fibroblast-based therapeutics throu
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology compan
FibroBiologics releases CYWC628 batch for DFU trial, clears cGMP checks, prepares enrollment; interi
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology compan
HC Wainwright & Co. analyst Matthew Caufield maintains FibroBiologics (NASDAQ:FBLG) with a Bu
Ordinary shares will continue to trade on the Nasdaq Capital Market, and the Company's listing o
https://data.epo.org/publication-server/publications/pdf?path=2026/16/DOC/EPNWB1/EP19795797NWB1/EP19
Shares of nCino Inc (NASDAQ: NCNO) jumped 18% in pre-market trading after reporting strong Q4 result
FibroBiologics completes first CYWC628 batch for diabetic foot ulcers trials, advances pipeline amid
The reverse stock split is expected to become effective at 12:01 a.m. Eastern Time on March 30, 2026
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology compa